Fact Sheet




The BioAlps cluster includes many different providers in different life science fields, from food and agriculture to human and animal health. From cell line selection to small batch production all the way through scale-up, researchers and companies will find exactly the technologies, products and services they require within the region.

Biotechnology can be defined as the use of microorganisms, such as bacteria or yeasts, or biological substances, such as enzymes, to perform specific industrial or manufacturing processes. Applications include the production of certain drugs, synthetic hormones, and bulk foodstuffs as well as the bioconversion of organic waste and the use of genetically altered bacteria in the cleanup of oil spills. Outsourcing parts of development and/or manufacturing can facilitate faster development times and more cost-effective solutions; the range of services that exist within BioAlps can satisfy even the most demanding companies and academics!


The EPFL Institute of Bioengineering (IBI) sits at the interface of the Life Sciences and Life Technologies, and bridges two EPFL Schools: the School of Life Sciences (FSV) and the School of Engineering (STI). With research groups led by faculty with backgrounds in cellular, molecular or computational biology, chemical or mechanical engineering, medicine, physics or physical chemistry, virology, or materials science and engineering, the Institute addresses questions in basic life sciences as well as their implications in human biology in health, disease, diagnostics and therapeutics.


Founded by four scientists of the University of Geneva, Epithelix develops, produces and sells reconstituted in vitro human tissues. Epithelix also offers research laboratories and chemical, cosmetic and pharmaceutical industries high-throughput screening services and testing of chemicals, based on its in vitro cell models. Epithelix also proposes toxicology and pharmacology tests of high quality, based on the use of primary human cells in 2D and 3D culture.

The University Hospitals of Geneva, Lausanne and Bern participate in numerous clinical trials sponsored by Swiss and international companies. They also participate in observational studies, such as, for example, the Swiss cohort study on intestinal inflammatory diseases.

This study unites six reference centres (Basel, Bern, Geneva, Lausanne, Saint Gallen and Zurich), financed by the Swiss National Fund for Science (FNS) and aims to identify therapies and management strategies to manage these diseases, taking into account genetic profiles, clinical treatment, psychological and economic factors of disease.


There are several Contract Research Organizations (CRO) in the BioAlps cluster, such as Frimorfo, SOCAR Research and Covance, which provide the full range of services from pre-clinical research to large scale international clinical trials.

Contract Manufacturing is within easy reach with companies such as Baccinex, BASF, Lonza, Orgamol and Sochinaz. Each with a specialised area of activity, they offer the life science industry world-class research, development and manufacturing from preclinical to commercial quantities of sterile liquid and lyophilised dosage forms, organic molecules, peptides, active pharmaceutical ingredients (APIs), chemical intermediates.

Protein production and yields in mammalian cell cultures are the specialty of ExcellGene and Selexis. ExcellGene is an established, science- and technology-driven service provider to the pharmaceutical and biotechnology industries. ExcellGene's technologies cover vectors, gene transfer systems, cell hosts, screening platforms for cells and processes, scale-up principles and bioreactors.

Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. Selexis technology improves the yield and stability of production cell lines and has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20-fold.

Syngenta is one of the world's leading companies dedicated to bringing plant potential to life. Monthey, in Western Switzerland, is the largest and one of the most significant Syngenta production sites worldwide. The site produces herbicides, fungicides and insecticides for the protection of the most important crops such as cotton, rice and corn. Through world-class science, global reach and commitment to customers, Syngenta helps to increase crop productivity, protect the environment and improve health and quality of life.


Join our network and let us know what you are doing. You can get in touch with us at: .

Find an actor

BioAlps World Visibitlity Package 201918.03.2019

A yearly international programme for our affiliated companies to increase their visibility.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn